AzTrials
AzTrials

Pelvic PainPelvic PainNCT06303609

Effects of Non-ablative Radiofrequency on Female Genito-pelvic Pain Disorder

A study testing nonablative radiofrequency and Vaginal dilator in people with Pelvic Pain, run by Centro de Atenção ao Assoalho Pélvico at 1 site in Brazil.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this randomized clinical trial is to verify the response of genito-pelvic pain disorders in women associated with inability to penetrate to the treatment with non-ablative radiofrequency. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Pelvic Pain
What is being tested?
nonablative radiofrequency and Vaginal dilator
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
56 participants
Where
1 siteBrazil
Study dates
20 Apr 2024to 20 Jul 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Women with genito-pelvic pain disorder associated to penetration.

Who cannot join

  • Chronic degenerative disease
  • Cognitive impairment
  • Genital agenesis
  • History of vaginal cancer or genital radiotherapy
  • Pelvic or lumbosacral prostheses
  • Cardiac pacemakers
Show all 11Show fewer
  • Pregnant women
  • Infections in the genital or systemic region
  • Any type of treatment for genito-pelvic pain disorder
  • Unstable relationship with the same partner
  • Partner with sexual complaints.

Trial locations and contacts

1 site in 1 country.

Tuffy Mamede, Post-graduation contact

+5571999673967

tuffy@tuffymamede.com

Patrícia Lordelo, Ph.D contact

pvslordelo@hotmail.com

Brazil1 site, 1 recruiting
  • Centro de Atenção ao Assoalho Pelvico

    Salvador, Estado de Bahia, 40.290-000

    Patricia V Lordelo, Phd, +5571988592400, pvslordelo@hotmail.com

    Recruiting

Other trials in Brazil

About this study

Official title: Effects of Non-ablative Radiofrequency on Female Genito-pelvic Pain Disorder: Randomized Clinical Trial

The goal of this randomized clinical trial is to verify the response of genito-pelvic pain disorders in women associated with inability to penetrate to the treatment with non-ablative radiofrequency. The main question it aims to answer is: Does non-ablative radiofrequency have a positive effect on the symptoms of genito-pelvic pain disorders associated with inability to penetrate? Before starting the intervention and at one week, one-, three- and six months after the end of the study, participants will be evaluated with 03 questionnaires (Female Sexual Function Index, Sexual Quality of Life and Perceived Stress Scale-10) and will score the visual analogue scale the level of pain with the penetration (from 0 to 10); participants will then undergo digital evaluation of the pelvic floor muscles, using vaginal dilators and electromyographic evaluation. After being randomized, participants will be divided into the Experimental Group and the Sham Group, being submitted to • the use of non-ablative radiofrequency in the anal and urogenital triangles, • the positioning of the vaginal dilator at the end of each session • and participants will be instructed to use the vaginal dilator at home daily. The researchers will compare the groups in relation to the ability to penetrate with reduced vaginal pain, sexual function, quality of sexual life and the correlation between pelvic muscle activity and perceived stress.

Read the detailed description

Initially, all women included in the study will be briefly and clearly instructed about genito-pelvic pain dysfunction and the anatomy of the pelvic floor. Then the participants will respond to the questionnaires FSFI (Female Sexual Function Index), SQoL-F (Scale of Female Sexual Quality of Life) and the PSS-10 (Perceived Stress Scale - 10).

The FSFI assesses the female sexual function index in the following domains: desire, arousal, lubrication, orgasm, satisfaction and pain. It is self-administered, contains 19 items, with an average response time of nine minutes and addresses aspects of the last four weeks. It is a measure to be considered a potential "gold standard" for evaluating therapeutically induced changes in female sexual function.

The SQoL-F measures the impact of female sexual dysfunctions on women's quality of life, addressing the items: psychosexual feelings, sexual and relationship satisfaction, self-invalidation and sexual repression. It is self-administered, contains 18 items, with an average response time of seven minutes and addresses aspects of the last four weeks.

The EPS-10 measures the degree of stress perceived by individuals within 30 days. It is validated in several countries in versions with 14 questions, 10 questions and four questions. The version with 10 questions was chosen for this study and is self-administered. The scale checks how much respondents evaluate their lives in terms of unpredictability, overload and lack of control, factors recognized as the most relevant factors in cases of stress.

After completing this first process, an Admission Form will be completed in two consecutive stages. In the first stage, the participant will be taken to a reserved location accompanied by at least one properly trained researcher, where questions 1 to 23 of the Admission Form will be answered, in which the following will be collected: demographic data, data social conditions, comorbidities, history of current and previous illness, gynecological history, obstetric history and fecal history, with application of the Rome III Criteria, Bristol Scale, and Visual Analogue Scale (VAS) related to pain during vaginal penetration.

Once the first stage of the Admission Form has been completed, the second stage will begin, in which the participant will be taken to a private office, where will be positioned in the supine position on a stretcher, with the pelvic region uncovered, the lower limbs abducted and flexed for perineal assessment. A trained researcher will carry out the physical evaluation through pelvic inspection and digital vaginal palpation, following the ICS recommendations, for using the letters P, E, R and F of the PERFECT Scheme, associated with a subjective assessment of coordination, use of accessory muscles and symmetry. The findings will be recorded in items 24 to 29 of the Admission Form.

Pelvic floor (PF) EMG will be performed using self-adhesive surface electrodes (Hydrogel Adhesive Electrode 4.5 x 3.8cm, Meditrace 200, Kendal™, Mansfield - USA) connected to an Electromyography (EMG) device (New Miotool Uro™, Miotec, Porto Alegre - BR) which converts the myoelectric signal into values expressed in microvolts (μV). EMG data will be collected and analyzed using Miotec Suite version 1.0 software (Miotec®, Porto Alegre, Brazil). In this software, the 20Hz high-pass, 500Hz low-pass and 60Hz notch filters will be used and the data can be viewed in the form of graphs. To perform the technique, the following materials will be needed: five surface electrodes, adhesive tape, 70% alcohol, paper towel and 2 pairs of gloves. 02 (two) surface electrodes will be attached, in the perianal region (positioning equivalent to 2 and 8 on the clock), 02 (two) on the trunk of the right external oblique muscle (to evaluate the abdominal muscles) and 01 (one) on the diaphysis of the right clavicle. To place the electrode in the perianal region, the patient is positioned in lateral decubitus with the lower limbs adducted and flexed. To place the electrode on the right external oblique muscle, the patient is positioned in DD with lower limbs extended and this muscle is asked to contract with trunk flexion and rotation to the left.

The examination will be carried out in two moments: the first moment with the patient in the supine position (DD) and in the second moment, in orthostasis. Initially, in DD, with the lower limbs extended, the EMG assessment will capture the Maximum Voluntary Contraction (MVC). 03 maximum contractions of the PFM (pelvic floor muscles) will be requested and the average of the 03 (three) contractions will be recorded. After recording the MVC, the collection of PF muscle activity in DD begins.

Collection 01: Starts with the collection of basal electrical activity for 30 seconds. The verbal command will be: "Keep your anus relaxed." The participant will then be asked to perform five tonic contractions (CT). The volunteer will be instructed to perform five contractions maintained for 10 seconds and the same relaxation time. The evaluator will determine when to contract and relax. The verbal command will be: "Contract your anus as if you were holding back a fart and hold for 10 seconds and then relax for the same amount of time. Do this five times following my voice command (Contract, hold, hold, hold... and relax.)." When finished, the participant will have to rest for 30 seconds. Finally, you will be asked to perform 10 maximum contractions of 1 second with complete relaxation between them (phasic contractions). The verbal command will be: "Contract your anus as if you were holding back a fart and relax. Do this ten times following my voice command (Contract, relax, contract, relax...)". After the phasic contractions, ask the patient to rest for ten seconds to complete the collection.

Collection 02: All the steps of collection 01 are repeated, but the orthostasis position will be adopted with the upper limbs along the body. All EMG collection will be recorded and analyzed by the Miotec Suite software version 1.0 (Miotec®, Porto Alegre, Brazil) and stored on a portable computer. During the entire examination, dynamic inspection will also be carried out (visual and by EMG, simultaneously) evaluating the presence of visible contraction of the PF muscles, the presence of contraction of other muscles (gluteus maximus, thigh adductors and abdominal muscles) and the visible relaxation capacity (good, regular, incomplete or absent).

After initial assessment, all patients will be randomized, using a random table generated in the program available on the website: www.random.org into two groups: a Radiofrequency Group (RG) made up of 28 women and a Control Group (CG) made up of by 28 participants. The volunteers who will be part of the GR group will receive physiotherapeutic treatment through the application of non-ablative RF with the aim of promoting perineal muscle relaxation. In each session, which will take place once a week, the patient will be taken to a private office and will be positioned in the supine position on a stretcher, with the pelvic region uncovered, the lower limbs abducted and flexed for the application of non-ablative RF through a trained researcher.

In women in the CG group, the device for applying non-ablative RF will be turned off and the conduction gel will be heated by a resistor. The remainder of the protocol will be identical to that of the RG group. Only the researcher who performed the procedure will know which group the patient belongs to, with allocation confidentiality being maintained for the other researchers and for the patient. Immediately after the application of RF, both in the RG group and in the CG group, a researcher who will not know which group the patient belongs to will try to introduce a lubricated vaginal dilator for 15 minutes, with the aim of promoting stretching of vaginal introitus.

There are six sizes of vaginal dilator that will be changed gradually with each session, depending on the patient's acceptability. In this study, the ABSOLOO vaginal dilator set will be used, which contains six devices with different colors and sizes: green nº 1: diameter 1.16cm, length 6.5cm; rose nº 2: diameter 1.90cm, length 7.5cm; yellow nº 3: diameter 2.15cm, length 8.7cm; purple nº 4: diameter 2.5cm, length 10.9cm; blue nº 5: diameter 3.10cm, length 13.20cm; and orange nº 6: diameter 3.5cm, length 14.5cm. The last size of vaginal dilator will be the one chosen by the patient. After the procedure, the patient will be instructed to exercise with the dilator at home daily for 15 minutes.

At the end of each session, the following will be recorded in the Monitoring Sheet: the tolerance of digital vaginal insertion, the size of the current dilator, the perception of VAS related to pain during vaginal penetration and the LIKERT scale of satisfaction in relation to the RF treatment . Eight RF application sessions will be held, weekly, totaling a period of two months.

One week after the last session, the final reassessment will be carried out, in which the participant will be taken to a private office, will be positioned in the supine position on a stretcher, with the pelvic region uncovered, the lower limbs abducted and flexed for the perineal assessment. and a trained researcher will carry out the evaluation through inspection, vaginal digital palpation, following the ICS recommendations, to use the letters P, E, R and F of the PERFECT Scheme associated with an evaluation as well. subjective coordination, use of accessory muscles and symmetry. An ABSOLOO vaginal dilator of the size chosen by the patient will be inserted and an electromyographic evaluation will be carried out.

The findings will be recorded in the Reassessment Form: tolerance of digital vaginal insertion, the size of the current dilator, the perception of VAS related to pain during vaginal penetration and the LIKERT scale of satisfaction in relation to treatment with RF. The FSFI, SQoL-F and EPS-10 instruments will also be answered again. After treatment, a follow-up period of one, three and six months will be carried out, when the Reassessment Form and the FSFI, SQoL-F and EPS-10 instruments will be reapplied.

If the patient does not attend the reevaluations, telephone contact will be made and the FSFI, SQoL-F and EPS-10 will be applied remotely. RF treatment will be considered successful based on the patient's ability to have sexual intercourse including complete penetration of the penis followed by the partner's ejaculation, without complaining of pain.

Conditions
Pelvic Pain
Being tested
nonablative radiofrequency, Vaginal dilator, Sham nonablative radiofrequency
Keywords
genito-pelvic pain disorder, radiofrequency, nonablative radiofrequency, women
Medical subject headings
Pelvic Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • nonablative radiofrequencyDevice

    The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the electrode. There will be a gradual increase in temperature, monitored by a digital infrared thermometer, to reach temperature between 36°C and 38°C, keeping the movement for two minutes in each area, spending in total around 10 minutes.

  • Vaginal dilatorDevice

    Both groups will use the vaginal dilator at the end of each session for 15 minutes and all patients will be advised to use it for 15 minutes daily in a home based treatment.

  • Sham nonablative radiofrequencyDevice

    The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the active electrode. As the device will not deliver the radiofrequency wave, the gel will be heated so the patient has the feeling of the temperature change, keeping the movement for two minutes in each area, spending in total around 10 minutes.

Study groups in NCT06303609
Study groupRoleWhat they receive
Radiofrequency groupExperimentalOnce a week, for 8 weeks, patient will undergo monopolar non-ablative radiofrequency application by a trained researcher.
Receives: Device: nonablative radiofrequency; Device: Vaginal dilator
Sham groupActive comparatorOnce a week, for 8 weeks, patient will undergo monopolar non-ablative radiofrequency application by a trained researcher, but the radiofrequency device will not emit the radiofrequency wave.
Receives: Device: Vaginal dilator; Device: Sham nonablative radiofrequency

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Penetration capacity with reduced vaginal pain

    To assess the primary outcome it will be used the Visual Analogue Scale (VAS) related to pain during vaginal penile penetration and during the vaginal dilatator penetration. The score varies from 0 (no pain) to 10 (maximum pain). Diminishing at least 2 points on the scale means positive diffence with the treatment. Also the change of the size of the vaginal dilatator will be a measure to positive response to the treatment. There are 6 sizes: green nº 1: diameter 1.16cm, length 6.5cm; rose nº 2: diameter 1.90cm, length 7.5cm; yellow nº 3: diameter 2.15cm, length 8.7cm; purple nº 4: diameter 2.5cm, length 10.9cm; blue nº 5: diameter 3.10cm, length 13.20cm; and orange nº 6: diameter 3.5cm, length 14.5cm

    Measured: From enrollment till 6 months after the end of treatment: at the assessment, before each session (8 sessions, one per week), one week after the last session, one, three and six months after the end of the treatment

Secondary outcomes (3)
  1. Sexual function

    To measure the change in the sexual function it will be use the Female Sexual Function Index. It consists of 19 items and the score varies from 2 to 36. A score below or equal to 26 indicates sexual dysfunction.

    Measured: From enrollment till 6 months after the end of treatment: at the assessment, before each session (8 sessions, one per week), one week after the last session, one, three and six months after the end of the treatment

  2. Quality of sexual life

    To measure the change in quality of sexual life it will be used the Scale of Female Sexual Quality of Life. It consists of 18 items, rated using a six-point scale (completely agree to completely disagree). The total score can range from 18 to 108 points. Higher scores indicate better female sexual quality of life.

    Measured: From enrollment till 6 months after the end of treatment: at the assessment, before each session (8 sessions, one per week), one week after the last session, one, three and six months after the end of the treatment

  3. Stress perception

    To measure the stress perception it will be used the Stress Perception Scale - 10. There are 10 items and the total score can range from 0 to 40. The higher scores indicate higher levels of perceived stress.

    Measured: From enrollment till 6 months after the end of treatment: at the assessment, before each session (8 sessions, one per week), one week after the last session, one, three and six months after the end of the treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2024
  2. Study start20 Apr 2024
  3. Primary completion20 Jun 2026 (estimated)
  4. Study completion20 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
56 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06303609
Sponsor's protocol ID
61102222.5.0000.5544
Acronym
Pelvic Pain
Status last verified
May 2024
First submitted
28 Nov 2023
Last updated
29 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing nonablative radiofrequency and Vaginal dilator in people with Pelvic Pain, run by Centro de Atenção ao Assoalho Pélvico at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tuffy Mamede, Post-graduation (+5571999673967, tuffy@tuffymamede.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Penetration capacity with reduced vaginal pain (time frame: From enrollment till 6 months after the end of treatment: at the assessment, before each session (8 sessions, one per week), one week after the last session, one, three and six months after the end of the treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in